Company intelligence / Profile preview

Inherent Biosciences

Salt Lake City, Utah, United Statesinherentbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Inherent Biosciences has commercialized an Epigenetic Sperm Quality Test (Path SpermQT) and is developing a second test for azoospermia. The company has secured a $1.9M Fast-Track SBIR grant from NIH to advance its azoospermia diagnostic.

Therapeutic areas: PsychiatryWomen's HealthImmunologyMen's Health
Modalities: Epigenetic diagnostics
Industry: Molecular Diagnostics

Drug pipeline

1 asset

Path SpermQT

Commercial

Indications: Male infertility, Sperm quality assessment

Partnerships

Baylor College of MedicineBoston IVFShady Grove FertilityUniversity of UtahBrigham Young UniversityWeill Cornell Medicine

Beyond the preview

Go deeper on Inherent Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inherent Biosciences.

Explore the full profile